Covid mRNA vaccines significantly increase the risk of cardiac arrest. Who are most at risk?

 Covid mRNA vaccines significantly increase the risk of cardiac arrest. Who are most at risk?

India's first mRNA Covid-19 vaccine Gennova's GEMCOVAC-19 will soon be available for emergency use.

Study found 84% increase in relative incidence of cardiovascular death within 28 days after COVID vaccination

COVID mRNA vaccines significantly increase the risk of cardiovascular death, especially in men aged 18 to 39 years. Speaking against their use, experts further advised that people with certain heart-related ailments should consult their doctor before taking these jabs.

Florida Surgeon General Dr. Joseph A. Ladapo said, "Today, we released an analysis on COVID-19 mRNA vaccines that the public needs to be aware of. This analysis found an increased risk of cardiovascular death in men 18-39." Shown. FL Won't be true but shut up, Ladapo tweeted.

The analysis was conducted by the Florida Department of Health (Department) through a self-controlled case series, a technique originally developed to evaluate vaccine safety.

The study found a sharp 84% increase in the relative incidence of cardiovascular death in men aged 18-39 years within 28 days following mRNA vaccination.

Who should be careful about getting the vaccine?

Patients with pre-existing heart conditions such as myocarditis and pericarditis should be extra cautious when considering vaccination and should discuss this with their healthcare provider.

It reads, the benefits of vaccination are likely to outweigh the unusually high risk of cardiovascular death in men in this age group, with high levels of global immunity to COVID-19. These increased risks were not found in non-mRNA vaccines.

"The study of the safety and efficacy of any drug, including vaccines, is an important component of public health," said Surgeon General Dr. Joseph Ladapo.

"There has been little attention to safety and concerns of many individuals have been dismissed – these are important findings that should be communicated to Floridians," Ladapo said.

Meanwhile, Genova's GEMCOVAC-19, India's first mRNA COVID-19 vaccine, will soon be available for emergency use. The company has conducted Phase 2 and Phase 3 data trials on 4000 participants to evaluate vaccine safety, immunogenicity and tolerability. India's drug regulator, the Drug Controller General of India (DCGI), is expected to give the vaccine an EUA soon.

According to Genoa officials, trial data showed that the vaccine was safe and well-tolerated. Immunogenicity measured 2 weeks after dosing showed that GEMCOVAC-19 is non-inferior to CoVShield.

The two-dose vaccine must be administered intramuscularly at 28-day intervals.